BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 18990124)

  • 1. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standard treatment and experimental targeted drug therapy for recurrent glioblastoma multiforme.
    Chang SM; Butowski NA; Sneed PK; Garner IV
    Neurosurg Focus; 2006 Apr; 20(4):E4. PubMed ID: 16709035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme.
    Chang JE; Khuntia D; Robins HI; Mehta MP
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):894-902, 907-15. PubMed ID: 18185489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular advances of brain tumors in radiation oncology.
    Noda SE; El-Jawahri A; Patel D; Lautenschlaeger T; Siedow M; Chakravarti A
    Semin Radiat Oncol; 2009 Jul; 19(3):171-8. PubMed ID: 19464632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
    Jagannathan J; Prevedello DM; Dumont AS; Laws ER
    Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted therapy for malignant glioma.
    Sathornsumetee S; Reardon DA; Desjardins A; Quinn JA; Vredenburgh JJ; Rich JN
    Cancer; 2007 Jul; 110(1):13-24. PubMed ID: 17520692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of nanoparticles for drug delivery in glioblastoma multiforme.
    Jain KK
    Expert Rev Neurother; 2007 Apr; 7(4):363-72. PubMed ID: 17425491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay.
    Glantz M; Kesari S; Recht L; Fleischhack G; Van Horn A
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S17-24. PubMed ID: 19660679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin.
    Katsetos CD; Dráberová E; Legido A; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):514-20. PubMed ID: 19650077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
    Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.
    Glas M; Hundsberger T; Stuplich M; Wiewrodt D; Kurzwelly D; Nguyen-Huu B; Rasch K; Herrlinger U
    Oncology; 2009; 76(3):184-9. PubMed ID: 19218824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.